Cargando…

Defibrotide Therapy for Sars CoV2 Acute Respiratory Distress Syndrome

Background: SARS-CoV-2 related acute respiratory distress syndrome (ARDS) is associated with endothelial dysfunction and profound dysregulation of the thrombotic/fibrinolytic pathway, with thrombotic complications common in affected patients (pts). Fibrin deposition may be a key feature of the patho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yanik, Gregory A, Frame, David, Scappaticci, Gianni Bruno, Maliarik, Mary, Pipe, Steven W, Braun, Thomas, Sisson, Thomas, Richardson, Paul G., Lawrence, Daniel A, Lama, Vibha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology. Published by Elsevier Inc. 2021
Materias:	332.Anticoagulation and Antithrombotic Therapies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701675/ http://dx.doi.org/10.1182/blood-2021-151417

Ejemplares similares

Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group
por: Moraleda, Jose M., et al.
Publicado: (2020)

Use of Defibrotide in Patients with COVID-19 Pneumonia; Results of the Defi-VID19 Phase 2 Trial
por: Ruggeri, Annalisa, et al.
Publicado: (2021)

Optimal Anticoagulant Dosing in Patients with COVID-19, a Retrospective Review
por: Carrillo, Alessandra, et al.
Publicado: (2021)

COVID-19 Associated Coagulopathy: Thrombosis, Hemorrhage and Mortality Rates with an Escalated-Thromboprophylaxis Strategy
por: Daughety, Molly, et al.
Publicado: (2020)

Edoxaban Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Hospitalized Patients with Atrial Fibrillation and COVID-19 Infection
por: Olivera, Pável E, et al.
Publicado: (2020)

Increasing Doses of Anticoagulation Are Associated with Improved Survival in Hospitalized COVID-19 Patients
por: Ionescu, Filip, et al.
Publicado: (2020)

COVID-19-Associated Coagulopathy: Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults with COVID-19
por: Chambers, Isaac, et al.
Publicado: (2020)

Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis
por: Goshua, George, et al.
Publicado: (2020)

Thrombotic Complications in a Canadian Population of Critically Ill Patients with COVID-19
por: Camille, Simard, et al.
Publicado: (2020)

Filter Clotting with Continuous Renal Replacement Therapy in COVID-19
por: Rosovsky, Rachel P., et al.
Publicado: (2020)

Anticoagulation Management and Outcomes in Covid-19 Patients:a Multi-Center Retrospective Cohort Study
por: Kaur, Jasmeet, et al.
Publicado: (2020)

The Role of D-Dimer for Optimal Thromboprophylaxis Strategy in Patients with COVID-19
por: Bhoopat, Lantarima, et al.
Publicado: (2020)

The Potential Role of Therapeutic Dose of Low Molecular Weight Heparin (LWMH) to Attenuate Hyper-Inflammatory State in Hospitalized COVID-19 Patients
por: Mughal, Mohsin Sheraz, et al.
Publicado: (2020)

Outcomes in COVID-19 Patients on Treatment Dose Anti-Coagulation Compared to Prophylactic Dose Anti-Coagulation
por: Kodama, Rich, et al.
Publicado: (2020)

The Impact of Different Prophylactic Anticoagulation Doses on the Outcomes of Patients with COVID-19
por: Jiménez-Soto, Rodolfo, et al.
Publicado: (2020)

The Elevation of LIVER Enzymes in Patients with Atrial Fibrillation and COVID-19 Is a Marker of Bad Evolution and Mortality
por: Cerezo Manchado, Juan Jose, et al.
Publicado: (2020)

Evaluation of Antiplatelet and Anticoagulation Therapy in High-Risk COVID-19 Patients
por: Ashraf, Farah, et al.
Publicado: (2020)

Clinical Outcomes in Critically-Ill Patients with COVID-19 Treated with Therapeutic Dose of Anticoagulants for Suspected Thromboembolism
por: Naing, Phyu Thin, et al.
Publicado: (2021)

Targeting the Endothelium in the Treatment of COVID-19 Early Clinical Stages: Results of a Randomized Placebo-Controlled Trial
por: Gonzalez-Ochoa, Alejandro
Publicado: (2021)

Extended Thromboprophylaxis in Patients with COVID-19
por: Zhao, Wei, et al.
Publicado: (2021)

The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists
por: Visser, Chantal, et al.
Publicado: (2021)

Defibrotide Therapy for SARS-CoV-2 ARDS
por: Frame, David, et al.
Publicado: (2022)

Rapid ECMO Training for Nurses in Response to the COVID-19 Pandemic
por: Toy, B., et al.
Publicado: (2021)

Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis
por: Tun, Han Naung, et al.
Publicado: (2022)

IMMUNE THROMBOCYTOPENIA PURPURA FLARE POST SARS-COV-2 VACCINATION
por: Ali, Elrazi, et al.
Publicado: (2021)

Perioperative Anticoagulation Management in Spine Surgery: Initial Findings From the AO Spine Anticoagulation Global Survey
por: Louie, Philip, et al.
Publicado: (2020)

Interest of the preventive and curative use of defibrotide on the occurrence and severity of sinusoidal obstruction syndrome after hematopoietic stem cell transplant in children
por: Rudebeck, Carl J., et al.
Publicado: (2022)

Pharmacokinetic profile of defibrotide in patients with renal impairment
por: Tocchetti, Paola, et al.
Publicado: (2016)

Defibrotide for hepatic veno-occlusive disease
Publicado: (2021)

Response to Maccio et al, “Multifactorial pathogenesis of COVID‐19‐related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?”
por: Richardson, Edward, et al.
Publicado: (2020)

Defibrotide in the treatment of hepatic veno-occlusive disease
por: Fulgenzi, Alessandro, et al.
Publicado: (2016)

Pharmacokinetics and Safety of Defibrotide in Healthy Japanese Subjects
por: Umemura, Kazuo, et al.
Publicado: (2016)

578. Infections in Patients Treated with Chimeric Antigen Receptor T-cells (CAR-T) therapy
por: Tran, Nikki, et al.
Publicado: (2020)

Defibrotide Has a Role in COVID-19 Therapy
por: Macciò, Antonio, et al.
Publicado: (2022)

La Organización de los Estados Americanos
por: Thomas, Ann Van Wynen
Publicado: (1968)

The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae
por: Richardson, Paul G., et al.
Publicado: (2021)

The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound
por: Wainberg, Mark, et al.
Publicado: (2014)

Endothelium-protective, histone-neutralizing properties of the polyanionic agent defibrotide
por: Shi, Hui, et al.
Publicado: (2021)

Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS)
por: Richardson, Paul, et al.
Publicado: (2019)

Respiratory Syncytial Virus Infection in Elderly Adults
por: Falsey, Ann R., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ccbql5jm80o8d3tgcdd8lc04fv